Analysis of molecular subtypes of breast cancer indicated that 23.31% of patients had luminal A subtype, 39.96% had luminal B1 (Her-2 negative) subtype, 13.22% had luminal B2 (Her-2 positive) subtype, 11.34% had Her-2 overexpression subtype, and 12.17% had triple-negative subtype. Here, ERBB2 is linked to breast cancer.